FDA stresses continuing efforts to maintain its strong oversight of generic drug quality issues

At the US Food and Drug Administration, “protecting patient and consumer health is our highest priority,” according to a statement issued on Friday by FDA Commissioner Dr Scott Gottlieb and director of the FDA’s Center for Drug Evaluation and Research, Dr Janet Woodcock.

Assessing and mitigating risks is at the heart of everything the agency does across its vast portfolio. Sometimes the actions taken are visible, like warning letters or recalls. At other times, actions to protect consumers are less discernable, but equally vital. Analyzing and addressing potential risks is a complex effort based on data and grounded in science. These activities are at the center of the FDA’s consumer protection mission and underpin its efforts to ensure the quality and safety of medical products, the officials said.

Assertions on generic drug quality ‘seriously flawed’